HOXA-AS3 and non-small cell lung carcinoma: Upregulation of HOXA cluster antisense RNA 3 (HOXA-AS3) in NSCLC confers drug resistance to cisplatin-based chemotherapy via downregulating HOXA3 expression (Table 2) [115].